Summary
There is continuous debate regarding the effectiveness of thymectomy in the treatment of non-thymomatous myasthenia gravis (MG). This systematic review was undertaken to determine whether thymectomy was effective in non-thymomatous MG. We retrieved articles published between January 1980 and September 2013. Sixteen cohort studies were included. Given the considerable heterogeneity, we used a descriptive method instead of statistical synthesis. The median relative rates (RRs) and their interquartile ranges were used to estimate the magnitude of benefit. Compared to conservatively treated MG patients, thymectomized patients had higher survival, clinical remission, pharmacologic remission and improvement rates, and RRs were 1.07 (1.01–1.17), 1.83 (0.82–2.99), 1.55 (1.22–1.95) and 1 (1.00–1.09), respectively. Subgroup analyses showed that patients with moderate to severe generalized MG benefited more from thymectomy, with RRs of survival and pharmacologic remission increasing to 1.35 (1.24–1.49) and 2.68 (1.73–4.17), respectively. These results suggested that thymectomy might be an effective procedure in non-thymomatous MG patients. The patients with moderate to severe generalized MG might benefit more. Taking into account the poor methodological quality of present studies, more well-designed prospective randomized controlled trials (RCTs) are still required to reach unequivocal conclusion.
Similar content being viewed by others
References
Zeldowicz LR, Saxton GD. Myasthenia gravis: comparative evaluation of medical and surgical treatment. Can Med Assoc J, 1969,101(10):88–93
Emeryk B, Strugalska MH. Evaluation of results of thymectomy in myasthenia gravis. J Neurol, 1976,211(2):155–168
Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000,55(1):7–15
Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci, 1981,377:678–690
Scadding GK, Havard CW, Lange MJ, et al. The long term experience of thymectomy for myasthenia gravis. J Neurol Neurosurg Psychiatry, 1985,48(5):401–406
Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med, 1972, 286(1):17–20
Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci, 1981,377:652–669
Grob D, Arsura EL, Brunner NG, et al. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci, 1987,505:472–499
Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry, 1998, 64(1):78–83
Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol, 1990,237(6):339–344
Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci, 1991,106(2):213–220
Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg, 2000,70(1):327–334
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998, 52(6):377–384
Cochrane Handbook for Systematic Reviews of Interventions Version 4. 2.6 [updated September 2006]: The Cochrane Collaboration; 2006. Available from: www.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf
Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci, 2003,998:413–423
Cosi V, Romani A, Lombardi M, et al. Prognosis of myasthenia gravis: a retrospective study of 380 patients. J Neurol, 1997,244(9):548–555
Valli G, Jann S, Premoselli S, et al. Myasthenia gravis treatment: twelve years experience on 110 patients. Ital J Neurol Sci, 1987,8(6):593–601
Wu WX, Wang N. Thymectomy for myasthenia gravis patients and related factors of efficacy. 2011
Bachmann K, Burkhardt D, Schreiter I, et al. Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement. Surgery, 2009,145(4):392–398
Werneck LC, Cunha FM, Scola RH. Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment. Acta Neurol Scand, 2000,101(1):41–46
Papatestas AE, Genkins G, Kornfeld P, et al. Effects of thymectomy in myasthenia gravis. Ann Surg, 1987, 206(1):79–88
Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve, 2010,41(3):370–374
Al-Moallem MA, Alkali NH, Hakami MA, et al. Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med, 2008, 28(5):341–345
Tsinzerling N, Lefvert AK, Matell G, et al. Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry, 2007,78(10):1109–1112
Kawaguchi N, Kuwabara S, Nemoto Y, et al. Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clin Neurol Neurosurg, 2007, 109(10):858–861
Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain, 2003,126 (Pt 10):2304–2311
Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry, 1998,65(4):492–496
Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol, 1997,244(2):112–118
Seto M, Motomura M, Takeo G, et al. Treatment of myasthenia gravis: a comparison of the natural course and current therapies. Tohoku J Exp Med, 1993,169(1):77–86
Donaldson DH, Ansher M, Horan S, et al. The relationship of age to outcome in myasthenia gravis. Neurology, 1990,40(5):786–790
Guillermo GR, Tellez-Zenteno JF, Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand, 2004, 109(3):217–221
Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol, 2005, 12(6):413–418
Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology, 2003,60(12):1978–1980
Kas J, Kiss D, Simon V, et al. Decade-long experience with surgical therapy of myasthenia gravis: early complications of 324 transsternal thymectomies. Ann Thorac Surg, 2001,72(5):1691–1697
Machens A, Busch C, Emskotter T, et al. Morbidity after transsternal thymectomy for myasthenia gravis: a changing perspective? Thorac Cardiovasc Surg, 1998, 46(1):37–40
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors contributed equally to the work.
This project was supported by grants from the National Nature Science Foundation of China (Nos. 81271406 and 81000537) and Program for New Century Excellent Talents in University of China (No. NCET-09-0394).
Rights and permissions
About this article
Cite this article
Luo, Y., Pan, Dj., Chen, Ff. et al. Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 34, 942–949 (2014). https://doi.org/10.1007/s11596-014-1378-x
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-014-1378-x